Interaction of nateglinide with KATP channel in β-cells underlies its unique insulinotropic action

European Journal of Pharmacology

Volumn 442, Issue 1-2, 2002, Pages 163-171

  Hu, Shiling ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Glucose sensitivity; KATP channel; Metabolic inhibition; Nateglinide; Pancreatic cell, rat

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; NATEGLINIDE; POTASSIUM; POTASSIUM CHANNEL; REPAGLINIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; METABOLIC INHIBITION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARBAMATES; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GLYBURIDE; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; KINETICS; MALE; MEMBRANE POTENTIALS; PHENYLALANINE; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 0037012670     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01499-1     Document Type: Article

References (47)

1. Possible therapy for postprandial hyperglycemia with strict glycemic control by a newly developed hypoglycemic agent, A-4166
2. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells
3. Electrophysiology of the pancreatic β-cell
4. Differential effects of short and long duration insulinotropic agents on meal related glucose excursion
5. Early insulin release effectively improves glucose tolerance: Studies in two rodent models of type 2 diabetes mellitus
6. + channel modification by metabolic inhibition in isolated guinea-pig ventricular myocytes
7. Clinical profile of glimepiride
8. Potassium selective ion channels in insulin-secreting cells: Physiology, pharmacology and other role in stimulus-secretion coupling
9. Insulin release in type 2 diabetes mellitus
10. Enzymatic, metabolic and secretory patterns in human islets of type 2 (non-insulin-dependent) diabetic patients
11. + channels during metabolic stress in cardiac muscle
12. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
13. Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) receptor in HIT T-15 cells
14. 2+ influx
15. Chronic effectiveness of a newly developed oral hypoglycemic agent (A-4166) in type II (non-insulin-dependent) diabetic rats
16. 2+ in pancreatic β-cells under metabolic inhibition
17. + channel in rat pancreatic B-cells
18. Metabolic, ionic and secretory response to D-glucose in islets from rats with acquired or inherited non-insulin-dependent diabetes
19. Effects of the hypoglycemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells
20. Effect of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic α- and β-cells: Comparative study with glibenclamide
21. Pancreatic β-cell KATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
22. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide
23. Electrophysiological and metabolic characterization of single beta-cells and islets from diabetic GK rats
24. Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine (A-4166)
25. ATP: An inward rectifier subunit plus the sulfonylurea receptor
26. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
27. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166
28. 3H] glimepiride
29. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells
30. Adenosine triphosphate-dependent K currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim
31. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide
32. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats
33. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family
34. Hypoglycemic effects of the novel antidiabetic agent repaglinide in rat and dogs
35. + channel block by sulfonylurea in pancreatic beta-cells
36. Control of insulin secretion by sulphonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets
37. Electrophysiology of the pancreas
38. A new in vitro model for the study of pancreatic A and B cells
39. Insulin production and glucose metabolism in isolated pancreatic islets of rats with NIDDM
40. Clinical profile of the novel sulfonylurea glimepiride
41. Possibility of ideal blood glucose control by a new oral hypoglycemic agent. N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) and its stimulatory effect on insulin secretion in animals
42. + channels and stimulation of insulin secretion by sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets
43. Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion
44. The sulfonylurea receptor may be an ATP-sensitive potassium channel
45. + channels and insulin secretion: Comparison with the sulfonylureas and nateglinide
46. Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine
47. + currents in pancreatic B-cells